Osborne Clarke advised NeRRe Therapeutics on the deal. The financing involved a syndicate of leading transatlantic life sciences investors led by new investor Columbus Venture Partners...
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here